Anito-cel moves closer to potential approval as Maryland-founded biotech becomes cornerstone asset in cell therapy expansion
In a defining move for the cell therapy sector, Gilead Sciences has entered into a definitive agreement to acquire Arcellx for an implied equity value of $7.8 billion.
The acquisition gives Gilead full ownership of anitocabtagene autoleucel (anito-cel), a late-stage BCMA-directed CAR T-cell therapy for relapsed or refractory multiple myeloma, and signals strong strategic conviction in the next phase of engineered cell therapy innovation.
More than a financial transaction, the deal consolidates science, platform technology, and commercial infrastructure under one roof — positioning Gilead to accelerate development and global commercialization while deepening its leadership in oncology cell therapy.
- Gilead Sciences will acquire Arcellx for $7.8 billion, gaining full ownership of late-stage CAR T therapy anito-cel – which has been co-developed under a collaboration agreement with Kite (a Gilead company) since 2022.
- Anito-cel’s BLA has been accepted by the FDA, with a PDUFA action date of December 23, 2026, positioning the therapy for potential approval in relapsed/refractory multiple myeloma.
- The deal consolidates Arcellx’s D-Domain platform and anito-cel under Gilead’s cell therapy franchise, including its Kite division, strengthening long-term strategy in oncology and next-generation cell therapy.
- The acquisition marks a major milestone for Maryland’s life sciences ecosystem, as a Germantown-founded biotech transitions from regional startup to cornerstone global oncology asset.
A Strategic Acceleration of Anito-cel
The agreement builds on a 2022 collaboration between the companies to co-develop and co-commercialize anito-cel. With the acquisition, Gilead eliminates the existing profit-share, milestone, and royalty structure, gaining full control over development strategy, manufacturing, and commercialization.
“This agreement reflects our conviction in the potential of anito-cel and our intention to move with speed so we can make the most of that potential for patients with multiple myeloma,” said Daniel O’Day, Chairman and Chief Executive Officer of Gilead Sciences. “Beyond the potential launch this year, anito-cel could become a foundational treatment for multiple myeloma over time, including earlier lines of therapy. In addition, the anito-cel D-domain BCMA binder could be important to our work in in vivo cell therapy, further strengthening our potential in oncology and inflammation.”
Under the terms of the merger agreement, Gilead will pay $115 per share in cash plus one non-transferable contingent value right (CVR) worth $5 per share if cumulative global net sales of anito-cel reach at least $6 billion from launch through year-end 2029. The offer represents a 68 percent premium to Arcellx’s 30-day volume-weighted average share price as of February 20, 2026. Gilead, which already owns approximately 11.5 percent of Arcellx’s outstanding shares, expects the transaction to close in the second quarter of 2026, subject to customary conditions.
Upon FDA approval, the transaction is expected to be accretive to earnings per share beginning in 2028.
The Clinical Profile and Platform Play
Anito-cel’s biologics license application (BLA) has been accepted by the U.S. Food and Drug Administration for fourth-line treatment of adult patients with relapsed or refractory multiple myeloma, with a Prescription Drug User Fee Act (PDUFA) action date of December 23, 2026. The submission is supported by results from a Phase 1 study and the pivotal Phase 2 iMMagine-1 trial.
In clinical studies to date, anito-cel has demonstrated deep and durable responses alongside what the company describes as a predictable and manageable safety profile — addressing key challenges historically associated with BCMA-targeted CAR T therapies.
But the strategic value extends beyond a single asset.
Arcellx’s proprietary D-Domain platform enables the development of novel binding domains designed for improved specificity and binding affinity. The D-domain BCMA binder used in anito-cel may have broader applications in next-generation CAR T constructs, bispecific antibodies, and potentially in vivo cell therapy approaches.
“The story of Arcellx is one of innovation, passion, resilience and teamwork. I could not be prouder of our team, our contribution to the myeloma field, and the impact anito-cel and our D-Domain platform are poised to have for patients and clinicians,” said Rami Elghandour, Chairman and Chief Executive Officer of Arcellx. “We are fortunate to have found a world-class partner in Gilead, which has the expertise to carry forward Arcellx’s legacy. Kite is well-positioned to maximize access to anito-cel, benefiting more patients, and the company’s commitment to be the leader in cell therapy is one I admire.”
The reference to Kite — Gilead’s cell therapy subsidiary — is central to understanding the operational strategy behind the acquisition.
Vertical Integration in a Complex Therapeutic Modality
Cell therapy has delivered some of the most profound responses in oncology, but it has also exposed structural challenges: manufacturing complexity, supply chain coordination, patient logistics, and cost constraints.
Owning the asset outright allows Gilead to fully align clinical development, manufacturing, regulatory strategy, and commercial execution. That alignment is particularly important in CAR T, where production scale, turnaround time, and process consistency directly affect patient access.
Kite already operates commercial cell therapy manufacturing infrastructure, including a facility in Maryland. That proximity to Arcellx’s Maryland roots is not incidental — it underscores how scientific innovation, clinical development, and commercial-scale manufacturing can converge within a single regional ecosystem.
In a sector where operational friction can slow adoption, geographic and organizational alignment can become a competitive advantage.
A Maryland Ecosystem Case Study
While the implications are global, the backstory is distinctly local.
Arcellx was founded in Maryland and launched out of Montgomery County’s Germantown Innovation Center on the PIC MC Campus. Founder, David Hilbert has deep roots in Maryland as a veteran biotech entrepreneur with a career that ties back to Human Genome Sciences where he served as Senior Vice President, Corporate Development. This latest deal now puts him at the center of two of Maryland’s most influential biotech success stories. From early-stage incubator space, the company scaled into a late-stage cell therapy developer with a platform compelling enough to command a $7.8 billion acquisition.
The 2022 co-development deal with Kite, a Gilead company that maintains a commercial cell therapy facility in Frederick, Maryland, adds another layer to the story. It signals that scientific innovation, clinical development partnerships, and commercial manufacturing capacity all coexisted within the state’s borders, and proximity can be a valuable element to accelerate collaboration and for deals like this getting their roots.
A Maryland-founded biotech partnered with a global biopharma that already had commercial infrastructure in the state. That alignment reduces friction, strengthens talent pipelines, and increases the likelihood that expertise remains embedded locally.
At a time when regions compete fiercely for life sciences investment, Maryland can now point to a fully integrated arc: startup incubation, platform innovation, late-stage clinical advancement, strategic partnership, and commercial manufacturing — all within the same geography.
Why This Deal Matters
For patients with relapsed or refractory multiple myeloma, the immediate focus is the upcoming FDA decision and the potential for expanded access to a differentiated CAR T therapy.
For Gilead, the acquisition reflects a long-term strategic commitment to cell therapy as a foundational oncology modality — not a niche experiment.
For Arcellx, it validates a platform approach built on rethinking binding domains and safety architecture.
And for Maryland, it reinforces that innovation ecosystems thrive when research, entrepreneurship, capital, and manufacturing infrastructure operate in proximity.
In a market where many biotechs are struggling to secure capital or reach late-stage milestones, a Maryland-founded company becoming a central strategic asset for a global cell therapy leader sends a powerful signal.
This is not just an acquisition. It is a consolidation of science, infrastructure, and geography — and a clear vote of confidence in the future of cell therapy.
